<DOC>
	<DOCNO>NCT00869128</DOCNO>
	<brief_summary>Objective - Type 2 uncontrolled diabetic patient often low endogenous melatonin suffer sleep disorder . The effect prolonged-release melatonin ( PRM ) formulation glucose lipid metabolism sleep study type 2 diabetes patient insomnia .</brief_summary>
	<brief_title>A Study Efficacy Prolonged-Release Melatonin Versus Placebo Diabetic Patients Suffering From Insomnia</brief_title>
	<detailed_description>Methods : In randomize , double-blind , crossover study , subject treat 3 week 1 tablet per night 2 mg prolonged-release melatonin placebo , one week washout period . Sleep objectively monitor wrist actigraphy . Fasting glucose , fructosamine , insulin , C-peptide , triglyceride , cholesterol ( total , HDL LDL ) antioxidant assess baseline end period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Diabetic patient proven presence disease complain insomnia . Patients liver renal problem ( serum creatinine 1.5 mg/dL ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>melatonin</keyword>
	<keyword>insomnia</keyword>
	<keyword>diabetes</keyword>
	<keyword>sleep</keyword>
</DOC>